BIOTRONIK Neuro, the neuromodulation division of Berlin-based global medical device company BIOTRONIK, has acquired a portfolio of intellectual property related to spinal cord stimulation (SCS) from Soin Neuroscience, a Dayton, Ohio-based medical device innovator founded by pain management physician Amol Soin, M.D. Financial terms were not disclosed. Soin Neuroscience will continue to operate as an independent company, with the transaction limited to the intellectual property underlying its spinal cord stimulation program.
The acquired patents cover spinal cord stimulation waveform design, adaptive programming, and the application of machine learning and artificial intelligence to neuromodulation therapy. The IP is intended to inform the development of a next-generation SCS program within BIOTRONIK Neuro’s chronic pain portfolio, complementing the company’s existing Prospera SCS System. Co-inventor Dr. Eric Schepis, PhD, contributed to a portion of the patents included in the transaction.
The acquisition follows a research collaboration announced in December 2025 in which Soin Neuroscience and BIOTRONIK Neuro evaluated novel waveforms and personalized SCS tuning approaches on the Prospera platform. That work established the technical and commercial foundation for today’s IP acquisition.
Spinal cord stimulation delivers electrical impulses to the spinal cord to interrupt pain signals before they reach the brain, offering an alternative to opioid-based chronic pain management. The next frontier in the field is adaptive, data-driven therapy — systems that adjust stimulation parameters in real time based on individual patient response rather than applying fixed waveforms. The Soin Neuroscience IP, with its focus on machine learning-driven personalization and adaptive programming, is directly targeted at that opportunity.
BIOTRONIK is a family-owned medical technology company with more than 60 years of history, known for introducing Germany’s first pacemaker in 1963 and subsequently building global businesses in cardiac rhythm management, electrophysiology, cardiac and vascular monitoring, and neuromodulation. BIOTRONIK Neuro is headquartered in Lake Oswego, Oregon. Soin Neuroscience was founded and built in Dayton, Ohio, where Dr. Soin serves as medical director of the Ohio Pain Clinic in Centerville.
KEY QUOTES:
“Spinal cord stimulation has helped countless patients manage chronic pain without relying on opioids, but there is still enormous room to make the therapy smarter, more personalized, and dynamic. BIOTRONIK Neuro has the scale, engineering depth, and commitment to neuromodulation to take these technologies further than we could on our own. This agreement lets that work continue inside an organization built to bring it to patients at scale. This is a proud moment not just for our company, but for Dayton and Ohio’s life sciences community. Innovation in medicine doesn’t have to come only from the coasts. We’ve built this technology here, and seeing it recognized by a company of BIOTRONIK’s caliber is validation of the work our team has put in over many years.”
Dr. Amol Soin, Founder and Chief Executive Officer, Soin Neuroscience
“Dr. Soin and his team have consistently pushed the boundaries of what personalized stimulation can look like, and this IP is a strong complement to our own SCS platform. Bringing these patents into BIOTRONIK Neuro reflects the natural next step in our relationship and reinforces our commitment to advancing neuromodulation science for the benefit of patients living with chronic pain.”
Andreas Gute, President, BIOTRONIK Neuro
